Cocrystal Pharma (COCP) Total Liabilities (2010 - 2026)
Cocrystal Pharma (COCP) posted Total Liabilities of $3.3 million for Q1 2026, down 2.1% sequentially from $3.4 million in Q4 2025, and down 1.34% YoY from $3.4 million in Q1 2025.
Cocrystal Pharma (COCP) Total Liabilities (2010 - 2026) Analysis & Trends
Cocrystal Pharma has reported Total Liabilities for 16 years, with the latest figure at $3.3 million in Q1 2026.
- Quarterly Total Liabilities fell 1.34% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 1.34% YoY) and the FY2025 annual result came in at $3.4 million, down 14.04% from the prior year.
- Total Liabilities fell to $3.3 million in Q1 2026 per COCP's latest filing, from $3.4 million in the prior quarter.
- Over five years, Total Liabilities peaked at $4.9 million in Q4 2023 and troughed at $1.3 million in Q4 2022.
- A 5-year average of $3.0 million and a median of $3.2 million in 2023 frame the typical range for Total Liabilities.
- The widest YoY moves for Total Liabilities: up 282.95% in 2023, down 46.59% in 2023.
- Over 5 years, Total Liabilities stood at $1.3 million in 2022, then jumped by 282.95% to $4.9 million in 2023, then fell by 19.32% to $3.9 million in 2024, then decreased by 14.04% to $3.4 million in 2025, then declined by 2.1% to $3.3 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $3.3 million, $3.4 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 10.03 Bn |
| 10 | Cocrystal Pharma | 16.13 Mn | 13.81 Mn | - | 3.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.61 Mn |
| Mar 31, 2026 | 3.31 Mn |
| Dec 31, 2025 | 3.38 Mn |
| Sep 30, 2025 | 2.78 Mn |
| Jun 30, 2025 | 3.17 Mn |
| Mar 31, 2025 | 3.36 Mn |
| Dec 31, 2024 | 3.93 Mn |
| Sep 30, 2024 | 3.53 Mn |
| Jun 30, 2024 | 4.18 Mn |
| Mar 31, 2024 | 3.96 Mn |
| Dec 31, 2023 | 4.88 Mn |
| Sep 30, 2023 | 1.92 Mn |
| Jun 30, 2023 | 1.60 Mn |
| Mar 31, 2023 | 3.17 Mn |
| Dec 31, 2022 | 1.27 Mn |
| Sep 30, 2022 | 1.74 Mn |
| Jun 30, 2022 | 2.99 Mn |
| Mar 31, 2022 | 1.79 Mn |
| Dec 31, 2021 | 1.84 Mn |
| Sep 30, 2021 | 1.59 Mn |